Muhamad Alhaj Moustafa, M.D., M.S., is a Hematologist and Medical Oncologist, with specialty interest in Lymphoma, Cellular Therapy, and Histiocytic diseases. His clinical and research focus includes: Hodgkin and Non-Hodgkin lymphoma, T-cell lymphomas, Post-transplant lymphoproliferative disorders, Rare subtypes of lymphoma, Histiocytic diseases, Radio-immunotherapy, Cellular therapy, Novel therapies for lymphoma.

 

Dr. Alhaj Moustafa's primary emphasis in the clinic is to enhance patients' comprehension of their condition and encourage them to participate as active partners in their healthcare management. Apart from his clinical responsibilities, Dr. Alhaj Moustafa is actively involved in research and education, serving as a mentor to medical students, residents, and fellows. He produces authoritative materials and publishes them in high-impact scientific journals.

Allison C. Rosenthal, DO, is an assistant professor of medicine at the Mayo Clinic in Phoenix, AZ. She is also the medical director of the Mayo Clinic’s Adolescent and Young Adult Cancer Program and co-directs the CAR-T program. Dr Rosenthal received her medical degree from Arizona College of Osteopathic Medicine of Midwestern University in Glendale, AZ. She then completed her residency in internal medicine at the Creighton University School of Medicine and her fellowship in hematology and medical oncology at the Mayo Clinic College of Medicine and Science, both in Phoenix, AZ. Dr Rosenthal is board certified in internal medicine, hematology, and medical oncology.

Dr Rosenthal treats patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Her clinical interests include the management and incorporation of novel treatment strategies for lymphomas, as well as the clinical care of the adolescent and young adult (AYA) population and their unique survivorship issues. Dr Rosenthal’s research interests include translational research (such as, bringing novel biomarkers into the clinic), participation in clinical trials looking at new drugs or combinations for patients with HL and NHL, and outcomes research (with a focus in the AYA population).